

CARACO PHARMACEUTICAL LABORATORIES LTD

Form 4

April 16, 2008

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
MOVENS DANIEL H

2. Issuer Name **and** Ticker or Trading
Symbol
CARACO PHARMACEUTICAL
LABORATORIES LTD [CPD]

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)

1150 ELIJAH MCCOY DRIVE

(Street)

DETROIT, MI 48202

3. Date of Earliest Transaction
(Month/Day/Year)
04/14/2008

☐ Director ☐ 10% Owner
☒ Officer (give title below) ☐ Other (specify below)

Chief Executive Officer

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check
Applicable Line)
☐ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
Common Stock	04/14/2008		S ⁽¹⁾	V Amount (A) or (D) Price 100 D \$ 16.83	29,900	D	
Common Stock	04/14/2008		S ⁽¹⁾	100 D \$ 16.87	29,800	D	
Common Stock	04/14/2008		S ⁽¹⁾	100 D \$ 16.88	29,700	D	
Common Stock	04/14/2008		S ⁽¹⁾	100 D \$ 16.89	29,600	D	
Common Stock	04/14/2008		S ⁽¹⁾	400 D \$ 16.9	29,200	D	

Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form 4

Common Stock	04/14/2008	<u>S⁽¹⁾</u>	200	D	\$ 16.92	29,000	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	200	D	\$ 16.93	28,800	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	200	D	\$ 16.94	28,600	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	200	D	\$ 16.95	28,400	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	400	D	\$ 16.97	28,000	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	300	D	\$ 16.98	27,700	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	500	D	\$ 16.99	27,200	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	100	D	\$ 17	27,100	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	200	D	\$ 17.02	26,900	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	100	D	\$ 17.04	26,800	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	98	D	\$ 17.05	26,702	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	202	D	\$ 17.08	26,500	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	300	D	\$ 17.09	26,200	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	200	D	\$ 17.1	26,000	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	100	D	\$ 17.16	25,900	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	100	D	\$ 17.17	25,800	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	100	D	\$ 17.2	25,700	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	200	D	\$ 17.22	25,500	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	400	D	\$ 17.29	25,100	D
Common Stock	04/14/2008	<u>S⁽¹⁾</u>	100	D	\$ 17.47	25,000	D

Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repor Trans (Instr
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
MOVENS DANIEL H 1150 ELIJAH MCCOY DRIVE DETROIT, MI 48202	X Chief Executive Officer

Signatures

Fred B. Green as
attorney-in-fact 04/16/2008

__Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) On March 14, 2008, the reporting person entered into a Rule 10b5-1 trading plan to sell up to 30,000 shares of common stock for estate and tax planning objectives. The reported sales were effected pursuant to such Rule 10b5-1 plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.